Therapix Biosciences Ltd (NASDAQ:TRPX) is expanding its cannabinoid-based clinical pipeline beyond neurological disorders to potentially treat obstructive sleep apnea (OSA), a chronic sleep disorder. The company is investigating the efficacy of THX-OSA01, an oral THC/PEA formulation, for the treatment of OSA in a 30-patient Phase IIa trial. In addition, Therapix is exploring the potential of a cannabinoid composition containing an antibacterial agent for the treatment of infectious diseases in preclinical trials. The company reported that the Phase IIa Tourette’s study will read out in H118 and the Phase I for mild cognitive impairment will begin in Q118.
THX-OSA01: A potential pharmacologic for OSA
Partnered with the Assuta Medical Center in Israel, the Phase IIa program is evaluating the efficacy of THX-OSA01 in 30 patients with confirmed OSA for one month. The primary efficacy endpoint is a significant decrease in the Apnea-Hypopnea Index (AHI), a metric for diagnosing and measuring OSA severity that represents the average number of breathing disturbances per one hour of sleep.
To read the entire report Please click on the pdf File Below: